EFFECACY OF GROWTH HORMONE THERAPY IN POSTMENOPAUSAL OBESE FEMALES

Abstract

Background: Growth hormone (GH) secretion is decreased in females with abdominal obesity, and this is accompanied by changed cardiovascular risk factors that result in metabolic syndrome. When GH was administered to females with abdominal obesity, their metabolic processes improved; however, there is insufficient information for females.
Aim: to analyze the effects of GH medication on visceral fat mass and glucose tolerance in postmenopausal females with abdominal obesity. It also assesses the effect of GH treatment on lowering abdominal visceral fat.
Methods: A total of 38 postmenopausal females were split into two groups at random, with one receiving placebo treatment and the other receiving growth hormone therapy. Results were derived from assessments of body parameters, insulin sensitivity, and glucose tolerance that were done at baseline (the beginning of treatment), six months, and twelve months after therapy.
Results: At six months, group II's serum levels of IGF-1 increased from 101±6.8 at baseline to 211±15.8 (p~0.001), whereas group I showed no statistically significant change from 121±4.8 to 119±5.8g/L. However, neither group showed a statistically significant difference from six to twelve months. After receiving GH treatment, group II's total triglycerides and HDL cholesterol increased after six months. After receiving GH treatment, visceral adipose tissue dramatically decreased in Group II, going from 177.0±8.5 to 170.4±9.8, while Group I had an increase, going from 161.1±7.7 to 172.0±8.7 (p=0.002).
Conclusion: The current study concludes that growth hormone therapy improves insulin sensitivity, lowers hepatic fat levels, and improves other metabolic syndrome characteristics in postmenopausal females with abdominal obesity.